DOP2021000017A - Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos - Google Patents

Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos

Info

Publication number
DOP2021000017A
DOP2021000017A DO2021000017A DO2021000017A DOP2021000017A DO P2021000017 A DOP2021000017 A DO P2021000017A DO 2021000017 A DO2021000017 A DO 2021000017A DO 2021000017 A DO2021000017 A DO 2021000017A DO P2021000017 A DOP2021000017 A DO P2021000017A
Authority
DO
Dominican Republic
Prior art keywords
prevent
same
pharmaceutical compositions
cancers including
pyrimidine compounds
Prior art date
Application number
DO2021000017A
Other languages
English (en)
Inventor
Hwan Bae In
Sook Kim Ji
Yul Choi Jae
Jong Kang Seok
Gil Ahn Young
Hyun Suh Kwee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2021000017A publication Critical patent/DOP2021000017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto de pirimidina representado por la Fórmula 1, un método para preparar el compuesto, y un uso farmacéutico del compuesto para la prevención o el tratamiento del cáncer.
DO2021000017A 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos DOP2021000017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180086768A KR101954370B1 (ko) 2018-07-25 2018-07-25 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
PCT/KR2019/001737 WO2020022600A1 (en) 2018-07-25 2019-02-13 Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

Publications (1)

Publication Number Publication Date
DOP2021000017A true DOP2021000017A (es) 2021-04-15

Family

ID=65760263

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000017A DOP2021000017A (es) 2018-07-25 2021-01-22 Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos

Country Status (16)

Country Link
US (2) US11292786B2 (es)
EP (1) EP3810601A4 (es)
JP (1) JP6806931B2 (es)
KR (1) KR101954370B1 (es)
CN (2) CN116693506A (es)
AR (1) AR119657A1 (es)
BR (1) BR112021001122A2 (es)
CA (1) CA3106961A1 (es)
CL (1) CL2021000175A1 (es)
DO (1) DOP2021000017A (es)
MX (1) MX2021000941A (es)
PE (1) PE20210373A1 (es)
PH (1) PH12021550124A1 (es)
SG (1) SG11202100076RA (es)
WO (1) WO2020022600A1 (es)
ZA (1) ZA202100485B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212153A1 (es) * 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
EA202290154A1 (ru) * 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2022098083A1 (ko) * 2020-11-05 2022-05-12 한미약품 주식회사 Flt3 억제제를 포함하는 백혈병 치료용 약학적 조성물
CA3211124A1 (en) * 2021-02-26 2022-09-01 Tyra Biosciences, Inc. Aminopyrimidine compounds and methods of their use
WO2022216097A1 (ko) * 2021-04-08 2022-10-13 주식회사 스탠다임 신규한 lrrk2 억제제
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58180010A (ja) * 1982-04-15 1983-10-21 Daihen Corp ３相用自動電圧調整装置のタツプ不揃い検出装置
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
US20110183975A1 (en) * 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN102471339A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
UA111272C2 (uk) * 2010-06-23 2016-04-11 Ханмі Сайєнс Ко., Лтд. Конденсовані піримідинові похідні для інгібування тирозинкіназної активності
TW201219383A (en) * 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
EP3489232A3 (en) * 2014-04-04 2019-07-31 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
WO2018139903A1 (ko) * 2017-01-26 2018-08-02 한미약품 주식회사 피리미딘 화합물 및 그의 의약 용도

Also Published As

Publication number Publication date
CL2021000175A1 (es) 2021-07-02
CN112469715A (zh) 2021-03-09
US20200255410A1 (en) 2020-08-13
CA3106961A1 (en) 2020-01-30
EP3810601A4 (en) 2022-04-20
WO2020022600A1 (en) 2020-01-30
EP3810601A1 (en) 2021-04-28
KR101954370B1 (ko) 2019-03-05
JP6806931B2 (ja) 2021-01-06
SG11202100076RA (en) 2021-02-25
US11292786B2 (en) 2022-04-05
JP2020527128A (ja) 2020-09-03
CN116693506A (zh) 2023-09-05
TW202014417A (zh) 2020-04-16
PE20210373A1 (es) 2021-02-26
ZA202100485B (en) 2023-11-29
US20230002358A1 (en) 2023-01-05
AR119657A1 (es) 2022-01-05
BR112021001122A2 (pt) 2021-04-13
MX2021000941A (es) 2021-03-09
PH12021550124A1 (en) 2021-09-27

Similar Documents

Publication Publication Date Title
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
BR112018007381A2 (pt) compostos úteis como imunomoduladores
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam